3 best performing ASX shares in the week of 10 October 2022
Marc Kennis, October 17, 2022
The 3 best performing ASX shares in the week of 3 October 2022
The 3 best performing ASX shares of the week starting 10 October 2022 were Cettire (ASX:CTT), up 46.4%, Nova Eye Medical (ASX:EYE), up 42.5%, and Element 25 (ASX:E25), up 34.2%.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
1. Cettire (ASX:CTT)
Industry: Consumer Discretionary
Cettire Limited (ASX:CTT) is a global online retailer, offering a selection of in-demand personal luxury goods via its website, cettire.com. Cettire has access to a catalogue of over 1,700 luxury brands and over 190,000 products of clothing, shoes, bags and accessories.
Market Cap: $505m
12 month high / low: $0.33 – $4.81
2. Nova Eye Medical (ASX:EYE)
Industry: Healthcare
Nova Eye Medical Limited (ASX:EYE, formerly Ellex Medical Lasers Limited) is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices.
Market Cap: $42m
12 month high / low: $0.18 – $0.42
3. Element 25 (ASX:E25)
Industry: Resources
Element 25 Limited (ASX:E25, formerly Montezuma Mining Company Ltd) rounds out the top 3 best performing ASX shares this week. E25 is a mineral exploration and mining company exploring for manganese, copper and gold deposits in Western Australia. The Company has a 100% interest in Yamarna Gold Project, Butcherbird Manganese-Copper Project and Green Dam Project.
Market Cap: $159m
12 month high / low: $0.425 – $2.05
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does
In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…
Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?
Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…